TR200201089T2 - Dipiridamol veya mopidamolün fibrine bağlı mikrodolaşım bozukluklarının tedavisi - Google Patents

Dipiridamol veya mopidamolün fibrine bağlı mikrodolaşım bozukluklarının tedavisi

Info

Publication number
TR200201089T2
TR200201089T2 TR2002/01089T TR200201089T TR200201089T2 TR 200201089 T2 TR200201089 T2 TR 200201089T2 TR 2002/01089 T TR2002/01089 T TR 2002/01089T TR 200201089 T TR200201089 T TR 200201089T TR 200201089 T2 TR200201089 T2 TR 200201089T2
Authority
TR
Turkey
Prior art keywords
fibrin
diseases
microcirculatory
mopidamol
dipyridamole
Prior art date
Application number
TR2002/01089T
Other languages
English (en)
Inventor
Eisert Wolfgang
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of TR200201089T2 publication Critical patent/TR200201089T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Bu bulusta, insan olan veya olmayan bir hayvan vücudunda fibrine bagli mikrodolasim hastaliklarini, örnegin metabolik hastaliklar, inflamatuar tepkimeler veya otobagisiklik hastaliklari gibi fibrine bagli mikrodolasim hastaliklari ve bunlardan baska periferal mikrodolasim bozukluklari veya artan hücre fragmantasyonu ile baglantili mikrodolasim bozukluklarini tedavi etmek için bir yöntem açiklanmistir ki söz konusu yöntem böyle bir tedaviye ihtiyaç duyan insan olan veya olmayan bir hayvan vücuduna, dipiridamol, mopidamol ve bunlarin farmasötik açidan kabul edilebilir tuzlarindan seçilen bir pirimido-pirimidin içeren bir farmasötik kompozisyondan etkili bir miktar vermekten meydana gelir. ayrica bu bulusta söz konusu pirimido-pirimidinin denk gelen bir farmasötik kompozisyonun üretimi için kullanimi tarif edilir.
TR2002/01089T 1999-10-22 2000-10-14 Dipiridamol veya mopidamolün fibrine bağlı mikrodolaşım bozukluklarının tedavisi TR200201089T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99121121A EP1093814A1 (en) 1999-10-22 1999-10-22 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders

Publications (1)

Publication Number Publication Date
TR200201089T2 true TR200201089T2 (tr) 2002-09-23

Family

ID=8239263

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01089T TR200201089T2 (tr) 1999-10-22 2000-10-14 Dipiridamol veya mopidamolün fibrine bağlı mikrodolaşım bozukluklarının tedavisi

Country Status (27)

Country Link
US (2) US20030149058A1 (tr)
EP (2) EP1093814A1 (tr)
JP (1) JP2003512431A (tr)
KR (1) KR20020040901A (tr)
CN (2) CN100411620C (tr)
AR (1) AR026197A1 (tr)
AU (1) AU784124B2 (tr)
BG (1) BG106609A (tr)
BR (1) BR0014946A (tr)
CA (1) CA2387486C (tr)
CZ (1) CZ20021487A3 (tr)
EA (1) EA200200448A1 (tr)
EE (1) EE200200214A (tr)
HK (1) HK1048597A1 (tr)
HR (1) HRP20020342A2 (tr)
HU (1) HUP0203249A3 (tr)
IL (1) IL148974A0 (tr)
MX (1) MXPA02003901A (tr)
NO (1) NO20021784D0 (tr)
NZ (1) NZ518525A (tr)
PE (1) PE20010747A1 (tr)
PL (1) PL354591A1 (tr)
SK (1) SK7112002A3 (tr)
TR (1) TR200201089T2 (tr)
WO (1) WO2001030353A1 (tr)
YU (1) YU30002A (tr)
ZA (1) ZA200203156B (tr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
DE10119680A1 (de) * 2001-04-20 2002-11-14 Boehringer Ingelheim Pharma Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
BR0213100A (pt) 2001-10-05 2004-11-30 Combinatorx Inc Combinações para o tratamento de distúrbios imuniinflamatórios
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
JP2006516593A (ja) * 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
WO2004093881A2 (en) * 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
JP2005060359A (ja) * 2003-08-13 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co Kg 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
AU2005245271A1 (en) 2004-05-13 2005-12-01 Boehringer Ingelheim International Gmbh Use of dipyridamole for treatment of resistance to platelet inhibitors
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
DE602006000819T2 (de) * 2006-02-09 2009-04-09 Teva Pharmaceutical Industries Ltd. Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung
US20100062066A1 (en) * 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
CN105473133A (zh) * 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
TW201503900A (zh) * 2013-07-29 2015-02-01 ren-zheng Lin 增強治療急性中風之抗血小板藥物之遞送方法及其組合物
WO2016119701A1 (en) 2015-01-28 2016-08-04 Realinn Life Science Limited COMPOUNDS FOR ENHANCING PPARγ EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF
KR101736832B1 (ko) 2017-02-28 2017-05-17 초당약품공업 주식회사 디피리다몰을 유효 성분으로 함유하는 신장 질환 치료용 의약 조성물
CN111346228B (zh) * 2018-12-21 2022-01-14 广州市妇女儿童医疗中心 胃肠道疾病的免疫机制及治疗药物
CN114432451B (zh) * 2018-12-21 2024-02-09 广州市妇女儿童医疗中心 胃肠道疾病的免疫机制及治疗药物
GB202006960D0 (en) * 2020-05-12 2020-06-24 Aplagon Oy Therapeutic
CN118477044A (zh) * 2023-02-13 2024-08-13 智泽童康(广州)生物科技有限公司 一种双嘧达莫的矫味组合物、干混悬剂及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
DE2735830A1 (de) * 1977-08-09 1979-03-01 Thomae Gmbh Dr K Antithrombotische arzneimittelkombination und verfahren zu ihrer herstellung
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
JPS6153271A (ja) * 1984-08-24 1986-03-17 Kaken Pharmaceut Co Ltd ローダニン誘導体
EP0169465B1 (de) * 1984-07-21 1990-02-28 Hoechst Aktiengesellschaft Kombinationspräparat aus Pyrimido-pyrimidinen und O-Acetylsalicylsäure bzw. deren pharmakologisch verträglichen Salzen und dessen Verwendung
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
US5242921A (en) * 1988-04-27 1993-09-07 Yale University Compositions and methods for treating cutaneous hyperproliferative disorders
SU1685450A1 (ru) * 1989-03-10 1991-10-23 Московский медицинский стоматологический институт им.Н.А.Семашко Способ лечени скаленус-синдрома при шейном остеохондрозе
IT1239064B (it) * 1990-05-14 1993-09-20 Fidia Spa Uso terapeutico del dipiridamolo
US5639482A (en) * 1993-11-10 1997-06-17 Crary; Ely J. Composition for control and prevention of diabetic retinopathy
CN1111985A (zh) * 1994-05-06 1995-11-22 王志刚 阿司匹林与潘生丁复方多层片的制备方法
US5498613A (en) * 1994-06-07 1996-03-12 The University Of Southern California Dipyridamole and analogs thereof in preventing adhesion formation
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US5620409A (en) * 1995-09-15 1997-04-15 The Research Foundation Of State University Of New York Method for inhibiting clot formation
CN1152436A (zh) * 1995-12-22 1997-06-25 王介明 一种治疗缺血性脑血管病和脑血栓的康复液及其制法
CA2293429A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
CN1108798C (zh) * 1999-01-26 2003-05-21 广东药学院 一种治疗、预防血栓形成及中风的复方制剂及其制备方法
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
DE10011482B4 (de) * 2000-03-09 2004-06-09 Fresenius Hemocare Gmbh Verfahren zum Herstellen eines Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Adsorbens und Verwendung des Adsorbens zur Herstellung eines Adsorbers
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US20020187187A1 (en) * 2001-04-21 2002-12-12 Toshimitsu Ohki Fast disintegrating meloxicam tablet
US7064103B2 (en) * 2002-01-04 2006-06-20 Becton, Dickinson And Company Binding protein as biosensors
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
JP2006516593A (ja) * 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
WO2004093881A2 (en) * 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors

Also Published As

Publication number Publication date
AU1272101A (en) 2001-05-08
US20030149058A1 (en) 2003-08-07
NZ518525A (en) 2004-04-30
HK1048597A1 (zh) 2003-04-11
CA2387486C (en) 2009-07-21
KR20020040901A (ko) 2002-05-30
PL354591A1 (en) 2004-01-26
HUP0203249A2 (hu) 2003-01-28
NO20021784L (no) 2002-04-16
CA2387486A1 (en) 2001-05-03
HUP0203249A3 (en) 2004-12-28
EA200200448A1 (ru) 2002-10-31
PE20010747A1 (es) 2001-07-24
BG106609A (bg) 2003-02-28
CZ20021487A3 (cs) 2002-10-16
IL148974A0 (en) 2002-11-10
JP2003512431A (ja) 2003-04-02
ZA200203156B (en) 2003-08-27
AR026197A1 (es) 2003-01-29
SK7112002A3 (en) 2002-09-10
HRP20020342A2 (en) 2003-10-31
EP1225900A1 (en) 2002-07-31
EP1093814A1 (en) 2001-04-25
CN1382052A (zh) 2002-11-27
EE200200214A (et) 2003-06-16
NO20021784D0 (no) 2002-04-16
BR0014946A (pt) 2002-06-18
MXPA02003901A (es) 2002-12-13
WO2001030353A1 (en) 2001-05-03
CN100411620C (zh) 2008-08-20
YU30002A (sh) 2004-12-31
CN1823780A (zh) 2006-08-30
US20080113934A1 (en) 2008-05-15
AU784124B2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
BRPI0014076B8 (pt) benzamidas e inibidores correlatos do fator xa
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
DE60027768D1 (de) Behandlung von metastatischer krankheit
WO2001030381A3 (de) Verwendung von csf-1-inhibitoren
JP2003509343A5 (tr)
EP1140840A4 (en) -G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREASINE AS RAF KINASE INHIBITORS
SE9900961D0 (sv) Novel compounds
ATE229533T1 (de) Nitrat-salze als arzneimittel
YU30002A (sh) Upotreba dipiridamola ili mopidamola u pripremanju leka za lečenje i prevenciju mikrocirkulacionih poremećaja koji zavise od fibrina
TR199901949T2 (tr) Lemfositik tümörler için çareler.
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
SE9802208D0 (sv) Novel compounds
IS2257B (is) Samsetning með aselínsýru
DE69633396D1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
TR200103398T2 (tr) íkameli fenilsikloheksankarboksamitler ve bunlarìn adenozin alìnìmìnìn inhibit”rleri olarak kullanìmì